NCT02478437

Brief Summary

This study is being done to determine whether cooled radiofrequency ablation (CRFA) on the medial branch nerves of the lumbar facet joint is effective for the treatment of low back pain. CRFA blocks the nerves that carry pain signals from joints in the lower back such that the brain does not receive the message that the low back is in pain. This technique is commonly performed by burning these nerves rather freezing them, but it is suspected that freezing them results in better pain relief. The CRFA blocks has been shown to effectively treat sacroiliac joint pain (a joint in the pelvis), which is another reason that it is suspected that CRFA will be effective when treating pain related to facet joints in the low back. We are performing this study in order to determine if that is the case.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at below P25 for phase_3 low-back-pain

Timeline
Completed

Started Jun 2015

Typical duration for phase_3 low-back-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

June 17, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 23, 2015

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

September 6, 2018

Status Verified

September 1, 2018

Enrollment Period

3.2 years

First QC Date

June 17, 2015

Last Update Submit

September 5, 2018

Conditions

Keywords

Lumbar Facet Syndrome

Outcome Measures

Primary Outcomes (1)

  • Pain improvement

    Percent of participants who reported 50% or greater improvement in pain

    6 months post-procedure

Secondary Outcomes (4)

  • Global pain score

    1 month, 3 months, 6 months and 12 months post procedure

  • McGill Pain Questionnaire (MPQ)

    1 month, 3 months, 6 months and 12 months post procedure

  • Pain Anxiety Symptom Scale short form (PASS-20)

    1 month, 3 months, 6 months and 12 months post procedure

  • Center for Epidemiologic Studies Depression short form index (CESD-10)

    1 month, 3 months, 6 months and 12 months post procedure

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.

Procedure: Conventional radiofrequency ablation (RFA)

Group 2

ACTIVE COMPARATOR

Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.

Procedure: Cooled Radiofrequency Ablation (CRFA)

Interventions

A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.

Group 1

Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.

Group 2

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with lumbar facet syndrome pain who would undergo treatment by lumbar medial branch radiofrequency ablation.
  • Low back pain for at least 6 months.
  • Pain resistant to conventional therapy including NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy or chiropractic care.
  • Pain diagram suggesting possibility of facet-mediated pain.
  • Referred pain when present not beyond the knee.
  • Positive response to at least 1 set of diagnostic intra-articular facet injections or medial branch blocks, defined as \> 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine).

You may not qualify if:

  • Focal neurologic signs or symptoms.
  • Radiologic evidence of a symptomatic herniated disc or nerve root impingement related to spinal stenosis.
  • Previous radiofrequency ablation treatment for similar symptoms.
  • Patient refusal.
  • Lack of consent.
  • Active systemic or local infections at the site of proposed needle and electrode placement.
  • Coagulopathy or other bleeding disorder, current use of anticoagulants or anti-platelet medications.
  • Allergy to medications being used for injection procedures (contrast dye, local anesthetic, IV sedative).
  • Inability to read English, communicate with staff, or participate in follow up.
  • Pregnancy.
  • Cognitive deficit.
  • Negative response to diagnostic intra-articular facet injections or medial branch blocks, defined as \< 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine).
  • Unstable medical or psychiatric illness.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anesthesiology Pain Managment Center

Chicago, Illinois, 60611, United States

Location

Related Publications (1)

  • McCormick ZL, Choi H, Reddy R, Syed RH, Bhave M, Kendall MC, Khan D, Nagpal G, Teramoto M, Walega DR. Randomized prospective trial of cooled versus traditional radiofrequency ablation of the medial branch nerves for the treatment of lumbar facet joint pain. Reg Anesth Pain Med. 2019 Mar;44(3):389-397. doi: 10.1136/rapm-2018-000035.

MeSH Terms

Conditions

Low Back Pain

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • David Walega, MD

    Northwestern University Feinberg School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Chief, Division of Pain Medicine

Study Record Dates

First Submitted

June 17, 2015

First Posted

June 23, 2015

Study Start

June 1, 2015

Primary Completion

August 1, 2018

Study Completion

August 1, 2018

Last Updated

September 6, 2018

Record last verified: 2018-09

Data Sharing

IPD Sharing
Will not share

Locations